An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
Christopher G. Wood(The University of Texas MD Anderson Cancer Center), Pramod K. Srivastava(University of Connecticut), Ronald M. Bukowski(Cleveland Clinic), Louis Lacombe(Hôtel-Dieu de Québec), Gorelov Ai(St Petersburg University), S. Gorelov(City Hospital No. 40), Peter Mulders(Radboud University Nijmegen), Henryk Zieliński(Centralny Szpital Kliniczny), Axel Hoos(Bristol-Myers Squibb (United States)), Florentina Teofilovici(Agenus (United States)), Leah Isakov(Agenus (United States)), Robert C. Flanigan(Loyola University Medical Center), Robert A. Figlin(City of Hope), Renu Gupta, Bernard Escudier(Institut Gustave Roussy)
Cited by 330
Abstract
Related Papers
No related papers found
Powered by citation graph analysis